Drug Trial Radar · NCT06610773
HUC-MSC for Treatment of High-risk HPV Infection
Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 1, 2024
Primary completion
Sep 10, 2025
Study completion Sep 10, 2026
Sponsor
- Lead sponsor
- Shanghai East HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 25 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and initial effectiveness of human umbilical cord mesenchymal stem cells in HPV clearance.
Conditions
- Human Papillomavirus Viruses
- Mesenchymal Stem Cells
Interventions
hUC-MSCsBiological
1×10\^6/Kg hUC-MSCs (suspended in 100 mL normal saline containing 5% albumin) are infused intravenously to patients at a controlled rate of 60-80 drops/min.
Saline+albuminBiological
Normal saline containing 5% albumin had a similar suspension and appearance package to hUC-MSCs, but no MSCs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events-The incidence rate of allergic reactionTime frame: 1day,1st,4th,12th,and 36th week
- The 24 type HPV viral loadTime frame: -28th~0day,4th,12th,and 36th week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Shanghai East Hospital, Tongji University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.